tbuckley/cabot-search huggingface dataset:
Hidden hurts: life with lichen sclerosus – a patient perspective
Authors: Elena Galentine, Camille M Powers, Leah McAleer, Sydney Rivera, Melissa M Mauskar
Journal: British Journal of Dermatology (2024)

A patient with vulvar lichen sclerosus bravely shares her experiences living with this hidden, painful, life-altering, and potentially stigmatizing vulvar dermatologic condition. Complemented by a clinician's perspective on the complexities of managing such patients, this piece aims to illuminate the numerous psychosocial challenges posed by lichen sclerosus. Through this dual narrative, we seek to deepen providers’ knowledge of the impact lichen sclerosus has on patients’ lives and the nuanced care required to support them.
Unraveling the Protein Post-translational Modification Landscape: Neuroinflammation and Neuronal Death after Stroke
Authors: Jin Tao, Jiaxin Li, Xiaochong Fan, Chao Jiang, Yebin Wang, Mengzhe Qin, Zahra Nikfard, Fatemeh Nikfard, Yunchao Wang, Ting Zhao, Na Xing, Marietta Zille, Junmin Wang, Jiewen Zhang, Xuemei Chen, Jian Wang
Journal: Ageing Research Reviews (2024)
Application of MIDD to accelerate the development of anti-infectives: Current status and future perspectives
Authors: Wen Yao Mak, Qingfeng He, Wenyu Yang, Nuo Xu, Aole Zheng, Min Chen, Jiaying Lin, Yufei Shi, Xiaoqiang Xiang, Xiao Zhu
Journal: Advanced Drug Delivery Reviews (2024)
Natural pachypodol integrated, lung targeted and inhaled lipid nanomedicine ameliorates acute lung injury via anti-inflammation and repairing lung barrier
Authors: Zhi-Chao Sun, Ran Liao, Caihong Xian, Ran Lin, Liying Wang, Yifei Fang, Zhongde Zhang, Yuntao Liu, Jun Wu
Journal: Journal of Controlled Release (2024)
DOR activation in mature oligodendrocytes regulates α-ketoglutarate metabolism leading to enhanced remyelination in aged mice
Authors: Guojiao Huang, Zhidan Li, Xuezhao Liu, Menglong Guan, Songlin Zhou, Xiaowen Zhong, Tao Zheng, Dazhuan Xin, Xiaosong Gu, Dezhi Mu, Yingkun Guo, Lin Zhang, Liguo Zhang, Q Richard Lu, Xuelian He
Journal: Nature Neuroscience (2024)
An open-source framework for end-to-end analysis of electronic health record data
Authors: Lukas Heumos, Philipp Ehmele, Tim Treis, Julius Upmeier Zu Belzen, Eljas Roellin, Lilly May, Altana Namsaraeva, Nastassya Horlava, Vladimir A Shitov, Xinyue Zhang, Luke Zappia, Rainer Knoll, Niklas J Lang, Leon Hetzel, Isaac Virshup, Lisa Sikkema, Fabiola Curion, Roland Eils, Herbert B Schiller, Anne Hilgendorff, Fabian J Theis
Journal: Nature Medicine (2024)

Abstract With progressive digitalization of healthcare systems worldwide, large-scale collection of electronic health records (EHRs) has become commonplace. However, an extensible framework for comprehensive exploratory analysis that accounts for data heterogeneity is missing. Here we introduce ehrapy, a modular open-source Python framework designed for exploratory analysis of heterogeneous epidemiology and EHR data. ehrapy incorporates a series of analytical steps, from data extraction and quality control to the generation of low-dimensional representations. Complemented by rich statistical modules, ehrapy facilitates associating patients with disease states, differential comparison between patient clusters, survival analysis, trajectory inference, causal inference and more. Leveraging ontologies, ehrapy further enables data sharing and training EHR deep learning models, paving the way for foundational models in biomedical research. We demonstrate ehrapy’s features in six distinct examples. We applied ehrapy to stratify patients affected by unspecified pneumonia into finer-grained phenotypes. Furthermore, we reveal biomarkers for significant differences in survival among these groups. Additionally, we quantify medication-class effects of pneumonia medications on length of stay. We further leveraged ehrapy to analyze cardiovascular risks across different data modalities. We reconstructed disease state trajectories in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) based on imaging data. Finally, we conducted a case study to demonstrate how ehrapy can detect and mitigate biases in EHR data. ehrapy, thus, provides a framework that we envision will standardize analysis pipelines on EHR data and serve as a cornerstone for the community.
Dual blockade of IL-10 and PD-1 leads to control of SIV viral rebound following analytical treatment interruption
Authors: Susan Pereira Ribeiro, Zachary Strongin, Hugo Soudeyns, Felipe Ten-Caten, Khader Ghneim, Gabriela Pacheco Sanchez, Giuliana Xavier de Medeiros, Perla Mariana Del Rio Estrada, Adam-Nicolas Pelletier, Timothy Hoang, Kevin Nguyen, Justin Harper, Sherrie Jean, Chelsea Wallace, Robert Balderas, Jeffrey D Lifson, Gopalan Raghunathan, Eric Rimmer, Cinthia Pastuskova, Guoxin Wu, Luca Micci, Ruy M Ribeiro, Chi Ngai Chan, Jacob D Estes, Guido Silvestri, Daniel M Gorman, Bonnie J Howell, Daria J Hazuda, Mirko Paiardini, Rafick P Sekaly
Journal: Nature Immunology (2024)

Human immunodeficiency virus (HIV) persistence during antiretroviral therapy (ART) is associated with heightened plasma interleukin-10 (IL-10) levels and PD-1 expression. We hypothesized that IL-10 and PD-1 blockade would lead to control of viral rebound following analytical treatment interruption (ATI). Twenty-eight ART-treated, simian immunodeficiency virus (SIV)mac
NETs activate Notch- γ secretase signaling in hidradenitis suppurativa
Authors: Christopher B Oliveira, Jorge Romo-Tena, Eduardo Patino-Martinez, Alexandra Woo, Angel S Byrd, Dongwon Kim, Ginette A Okoye, Mariana J Kaplan, Carmelo Carmona-Rivera
Journal: Journal of Allergy and Clinical Immunology (2024)
Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial
Authors: Boris Julg, Victoria E K Walker-Sperling, Kshitij Wagh, Malika Aid, Kathryn E Stephenson, Rebecca Zash, Jinyan Liu, Joseph P Nkolola, Amelia Hoyt, Mike Castro, Leonid Serebryannyy, Katherine Yanosick, Tessa Speidel, Erica N Borducchi, Tetyana Murzda, Lori Maxfield, Roberto Arduino, Adrian B McDermott, Lucio Gama, Elena E Giorgi, Richard A Koup, Michael S Seaman, Charlotte-Paige Rolle, Edwin DeJesus, Wenjun Li, Bette Korber, Dan H Barouch
Journal: Nature Medicine (2024)

Human immunodeficiency virus type 1 (HIV-1)-specific broadly neutralizing monoclonal antibodies (bNAbs) have to date shown transient viral suppression when administered as monotherapy or as a cocktail of two antibodies
The European Health Data Space can be a boost for research beyond borders
Authors: Andrea Ganna, Angel Carracedo, Christian F Christiansen, Emanuele Di Angelantonio, Pearl A Dykstra, Angel M Dzhambov, Roland Eils, Sara Green, Katharina L Schneider, Tibor V Varga, Anna-Leena Vuorinen, Luisa Zuccolo, Naja Hulvej Rod, Klaus Hoeyer
Journal: Nature Medicine (2024)
Aged bone marrow macrophages drive systemic aging and age-related dysfunction via extracellular vesicle-mediated induction of paracrine senescence
Authors: Jing Hou, Kai-Xuan Chen, Chen He, Xiao-Xiao Li, Mei Huang, Yang-Zi Jiang, Yu-Rui Jiao, Qiao-Ni Xiao, Wen-Zhen He, Ling Liu, Nan-Yu Zou, Min Huang, Jie Wei, Ye Xiao, Mi Yang, Xiang-Hang Luo, Chao Zeng, Guang-Hua Lei, Chang-Jun Li
Journal: Nature Aging (2024)

The accumulation and systemic propagation of senescent cells contributes to physiological aging and age-related pathology. However, which cell types are most susceptible to the aged milieu and could be responsible for the propagation of senescence has remained unclear. Here we found that physiologically aged bone marrow monocytes/macrophages (BMMs) propagate senescence to multiple tissues, through extracellular vesicles (EVs), and drive age-associated dysfunction in mice. We identified peroxisome proliferator-activated receptor α (PPARα) as a target of microRNAs within aged BMM-EVs that regulates downstream effects on senescence and age-related dysfunction. Demonstrating therapeutic potential, we report that treatment with the PPARα agonist fenofibrate effectively restores tissue homeostasis in aged mice. Suggesting conservation to humans, in a cohort study of 7,986 participants, we found that fenofibrate use is associated with a reduced risk of age-related chronic disease and higher life expectancy. Together, our findings establish that BMMs can propagate senescence to distant tissues and cause age-related dysfunction, and they provide supportive evidence for fenofibrate to extend healthy lifespan.
Five latent factors underlie response to immunotherapy
Authors: Joseph Usset, Axel Rosendahl Huber, Maria A Andrianova, Eduard Batlle, Joan Carles, Edwin Cuppen, Elena Elez, Enriqueta Felip, Marina Gómez-Rey, Deborah Lo Giacco, Francisco Martinez-Jimenez, Eva Muñoz-Couselo, Lillian L Siu, Josep Tabernero, Ana Vivancos, Ferran Muiños, Abel Gonzalez-Perez, Nuria Lopez-Bigas
Journal: Nature Genetics (2024)

Only a subset of patients treated with immune checkpoint inhibitors (CPIs) respond to the treatment, and distinguishing responders from non-responders is a major challenge. Many proposed biomarkers of CPI response and survival probably represent alternative measurements of the same aspects of the tumor, its microenvironment or the host. Thus, we currently ignore how many truly independent biomarkers there are. With an unbiased analysis of genomics, transcriptomics and clinical data of a cohort of patients with metastatic tumors (n = 479), we discovered five orthogonal latent factors: tumor mutation burden, T cell effective infiltration, transforming growth factor-beta activity in the microenvironment, prior treatment and tumor proliferative potential. Their association with CPI response and survival was observed across all tumor types and validated across six independent cohorts (n = 1,491). These five latent factors constitute a frame of reference to organize current and future knowledge on biomarkers of CPI response and survival.
Widespread position-dependent transcriptional regulatory sequences in plants
Authors: Yoav Voichek, Gabriela Hristova, Almudena Mollá-Morales, Detlef Weigel, Magnus Nordborg
Journal: Nature Genetics (2024)

Much of what we know about eukaryotic transcription stems from animals and yeast; however, plants evolved separately for over a billion years, leaving ample time for divergence in transcriptional regulation. Here we set out to elucidate fundamental properties of cis-regulatory sequences in plants. Using massively parallel reporter assays across four plant species, we demonstrate the central role of sequences downstream of the transcription start site (TSS) in transcriptional regulation. Unlike animal enhancers that are position independent, plant regulatory elements depend on their position, as altering their location relative to the TSS significantly affects transcription. We highlight the importance of the region downstream of the TSS in regulating transcription by identifying a DNA motif that is conserved across vascular plants and is sufficient to enhance gene expression in a dose-dependent manner. The identification of a large number of position-dependent enhancers points to fundamental differences in gene regulation between plants and animals.
Simplified Gambogic Acid Prodrug Nanoparticles to Improve Efficiency and Reduce Toxicity for Clinical Translation Potential
Authors: Ruyi Wang, Yuxiao Xiao, Zhongtao Zhang, Xiaoxian Huang, Wanfang Zhu, Xiao Ma, Feng Feng, Wenyuan Liu, Lingfei Han, Wei Qu
Journal: Advanced Healthcare Materials (2024)

Abstract Poor in vivo characteristics of gambogic acid (GA) and difficulties in industrial manufacturing of its nanocarriers have hindered its clinical translation. Therefore, a reproducible nano‐drug delivery system must be developed to realize simpler manufacture and address inherent defects of GA, such as short circulation and severe side effects, in order to facilitate its clinical application. Herein, a drug self‐assembled nanoparticles (NPs) consisting of a hydrophobic prodrug based on GA and oleyl alcohol (OA), as well as vitamin E‐polyethylene glycol succinate (TPGS) as a shield to improve the stability of the NPs is reported. The preparation method is simple enough to stably facilitate large‐scale manufacturing. The self‐assembled NPs exhibit a remarkably high drug‐loading capacity, and their prolonged circulation enables the NPs to demonstrate superior antitumor efficacy in both cellular and animal models. The flexible hydrophobic long chain wraps GA groups, which mitigates vascular irritation and reduces hemolysis rates. Consequently, the prodrug nano‐system addresses GA‐related concerns regarding stability, efficacy, and safety, offering a simple, stable, and secure nano‐platform for similar candidate drugs.
Diurnal variation of postoperative delirium in elderly patients undergoing esketamine anesthesia for elective noncardiac surgery: a randomized clinical trial
Authors: Yuan Zhang, Rong Chen, Shan Tang, Tao Sun, Yanli Yu, Ruoshi Shi, Kai Wang, Zi Zeng, Xinhang Liu, Qingtao Meng, Zhongyuan Xia
Journal: International Journal of Surgery (2024)
Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma)
Authors: Olivier Tournilhac, Bettina Altmann, Birte Friedrichs, Kamal Bouabdallah, Mathieu Leclerc, Guillaume Cartron, Pascal Turlure, Peter Reimer, Eva Wagner-Drouet, Laurence Sanhes, Roch Houot, Murielle Roussel, Frank Kroschinsky, Peter Dreger, Andreas Viardot, Laurence de Leval, Andreas Rosenwald, Philippe Gaulard, Gerald Wulf, Alban Villate, Christelle Latiere, Ahmet Elmaagacli, Bertram Glass, Viola Poeschel, Gandhi Damaj, David Sibon, Eric Durot, Karin Bilger, Anne Banos, Mathias Haenel, Martin Dreyling, Ulrich Keller, Mourad Tiab, Bernard Drenou, Jérome Cornillon, Stéphanie Nguyen, Marie Robin, Maike Nickelsen, Lorenz Trümper, Georg Lenz, Marita Ziepert, Norbert Schmitz
Journal: Journal of Clinical Oncology (2024)

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Primary analysis of the phase III randomized AATT study showed that younger patients with peripheral T-cell lymphoma (PTCL) consolidated with autologous or allogeneic transplantation (alloSCT) had similar event-free survival (EFS) and overall survival (OS). Seven-year EFS of patients randomly assigned to alloSCT was 38% (95% CI, 25 to 52) compared with 34% (95% CI, 22 to 47) for patients randomly assigned to autologous transplantation of hematopoietic stem cells (autoSCT); OS was 55% (95% CI, 41 to 69) and 61% (95% CI, 47 to 74). Among patients undergoing alloSCT (n = 26) or autoSCT (n = 41) on study, the cumulative progression/relapse rate was 8% (95% CI, 0 to 19) and 55% (95% CI, 35 to 74). Nonrelapse mortality (NRM) was 31% (95% CI, 13 to 49) and 3% (95% CI, 0 to 8) after alloSCT and autoSCT, respectively. Fifteen of 30 patients with early progression and 11 of 20 patients with progression/relapse after autoSCT received alloSCT. Seven-year OS after salvage alloSCT was 61% (95% CI, 47 to 74); NRM was 23% (95% CI, 6 to 40). Long-term follow-up documents the strong graft versus lymphoma effect of alloSCT independent of the timing of transplantation. Survival of patients unable to undergo transplantation was dismal. AlloSCT is the treatment of choice for younger, transplant-eligible patients with relapsed/refractory PTCL. AlloSCT is currently not recommended as part of first-line consolidation.
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
Authors: Domenica Lorusso, Yang Xiang, Kosei Hasegawa, Giovanni Scambia, Manuel Leiva, Pier Ramos-Elias, Alejandro Acevedo, Jakub Cvek, Leslie Randall, Andrea Juliana Pereira de Santana Gomes, Fernando Contreras Mejía, Limor Helpman, Hüseyin Akıllı, Jung-Yun Lee, Valeriya Saevets, Flora Zagouri, Lucy Gilbert, Jalid Sehouli, Ekkasit Tharavichitkul, Kristina Lindemann, Nicoletta Colombo, Chih-Long Chang, Marketa Bednarikova, Hong Zhu, Ana Oaknin, Melissa Christiaens, Edgar Petru, Tomoka Usami, Peng Liu, Karin Yamada, Sarper Toker, Stephen M Keefe, Sandro Pignata, Linda R Duska
Journal: The Lancet (2024)
Health Insurance Continuity and Mortality in Children and Adolescents/Young Adults with Blood Cancer
Authors: Xu Ji, Xinyue (Elyse) Zhang, K Robin Yabroff, Wendy Stock, Patricia Cornwell, Shasha Bai, Ann C Mertens, Joseph Lipscomb, Sharon M Castellino
Journal: JNCI Journal of the National Cancer Institute (2024)

Abstract Background Many uninsured patients do not receive Medicaid coverage until a cancer diagnosis, potentially delaying access to care for early cancer detection and treatment. We examine the association of Medicaid enrollment timing and patterns with survival among children and adolescents/young adults (AYAs) diagnosed with blood cancers, where disease onset can be acute and early detection is critical. Methods We identified 28,750 children and AYAs (0-39 years) newly diagnosed with blood cancers from the 2006-2013 SEER-Medicaid data. Enrollment patterns included continuous Medicaid (preceding through diagnosis), newly gained Medicaid (at/shortly after diagnosis), other noncontinuous Medicaid enrollment, and private/other insurance. We assessed cumulative incidence of death from diagnosis, censoring at last follow-up, five years post-diagnosis, or December 2018, whichever occurred first. Multivariable survival models estimated the association of insurance enrollment patterns with risk of death. Results One-fourth (26.1%) of the cohort were insured by Medicaid; of these, 41.1% had continuous Medicaid, 34.9% had newly gained Medicaid, and 24.0% had other noncontinuous enrollment. The cumulative incidence of all-cause death five-year post-diagnosis was highest in patients with newly gained Medicaid (30.2%, 95%CI = 28.4-31.9%), followed by other noncontinuous enrollment (23.2%, 95%CI = 21.3-25.2%), continuous Medicaid (20.5%, 95%CI = 19.1-21.9%), and private/other insurance (11.2%; 95%CI = 10.7-11.7%). In multivariable models, newly gained Medicaid was associated with a higher risk of all-cause (hazard ratio = 1.39, 95%CI = 1.27-1.53) and cancer-specific death (hazard ratio = 1.50, 95%CI = 1.35-1.68), compared to continuous Medicaid. Conclusions Continuous Medicaid coverage is associated with survival benefits among pediatric and AYA patients diagnosed with blood cancers; however, less than half of Medicaid-insured patients have continuous coverage before diagnosis.
Histopathological response to chemotherapy and survival of mucinous type gastric cancer
Authors: Irene A Caspers, Astrid E Slagter, Pauline A J Vissers, Martha Lopez-Yurda, Laurens V Beerepoot, Jelle P Ruurda, Grard A P Nieuwenhuijzen, Suzanne S Gisbertz, Mark I van Berge Henegouwen, Henk H Hartgrink, Danny Goudkade, Liudmila L Kodach, Johanna W van Sandick, Marcel Verheij, Rob H A Verhoeven, Annemieke Cats, Nicole C T van Grieken
Journal: JNCI Journal of the National Cancer Institute (2024)

Abstract Background Data on the clinicopathological characteristics of mucinous gastric cancer (muc-GC) are limited. This study compares the clinical outcome and response to chemotherapy between patients with resectable muc-GC, intestinal (int-GC), and diffuse (dif-GC) gastric cancer. Methods Patients from the D1/D2 study or the CRITICS trial were included in exploratory surgery-alone (SAtest) or chemotherapy test (CTtest) cohorts. Real-world data from the Netherlands Cancer Registry on patients treated between with surgery alone (SAvalidation) and receiving preoperative chemotherapy with or without postoperative treatment (CTvalidation) were used for validation. Histopathological subtypes were extracted from pathology reports filed in the Dutch Pathology Registry and correlated with tumor regression grade (TRG) and relative survival (RS). Results In the SAtest (n = 549) and SAvalidation (n = 8062) cohorts, muc-GC patients had a 5-year RS of 39% and 31%, similar to or slightly better than dif-GC (43% and 29%, P = .52 and P = .011), but worse than int-GC (55% and 42%, P = .11 and P &amp;lt; .001). In the CTtest (n = 651) and CTvalidation (n = 2889) cohorts, muc-GC showed favorable TRG (38% and 44% (near-) complete response) compared with int-GC (26% and 35%) and dif-GC (10% and 28%, P &amp;lt; .001 and P = .005). The 5-year RS in the CTtest and CTvalidation cohorts for muc-GC (53% and 48%) and int-GC (58% and 59%) was significantly better compared with dif-GC (35% and 38%, P = .004 and P &amp;lt; .001). Conclusion Recognizing and incorporating muc-GC into treatment decision-making of resectable GC can lead to more personalized and effective approaches, given its favorable response to preoperative chemotherapy in relation to int-GC and dif-GC and its favorable prognostic outcomes in relation to dif-GC.
Early bone marrow alterations in patients with adenosine deaminase 2 deficiency across disease phenotypes and severities
Authors: Dimitri Bulté, Federica Barzaghi, Cristina Mesa-Nuñez, Chiara Rigamonti, Luca Basso-Ricci, Camilla Visconti, Stefania Crippa, Emanuela Pettinato, Diego Gilioli, Raffaella Milani, Pamela Quaranta, Roberta Caorsi, Alessia Cafaro, Giuliana Cangemi, Michela Lupia, Francesca Schena, Alice Grossi, Giulia Di Colo, Silvia Federici, Antonella Insalaco, Fabrizio De Benedetti, Sarah Marktel, Raffaella Di Micco, Maria Ester Bernardo, Serena Scala, Maria Pia Cicalese, Francesca Conti, Maurizio Miano, Marco Gattorno, Carlo Dufour, Alessandro Aiuti, Alessandra Mortellaro
Journal: Journal of Allergy and Clinical Immunology (2024)
A phosphoglycerate mutase 1 allosteric inhibitor restrains TAM-mediated colon cancer progression
Authors: Cheng Wang, Minghao Zhang, Shunyao Li, Miaomiao Gong, Ming-Yu Luo, Mo-Cong Zhang, Jing-Hua Zou, Ningxiang Shen, Lu Xu, Hui-Min Lei, Ling Bi, Liang Zhu, Zhengting Wang, Hong-Zhuan Chen, Lu Zhou, Ying Shen
Journal: Acta Pharmaceutica Sinica B (2024)

Colorectal cancer (CRC) is a prevalent malignant tumor often leading to liver metastasis and mortality. Despite some success with PD-1/PD-L1 immunotherapy, the response rate for colon cancer patients remains relatively low. This is closely related to the immunosuppressive tumor microenvironment mediated by tumor-associated macrophages (TAMs). Our previous work identified that a phosphoglycerate mutase 1 (PGAM1) allosteric inhibitor, HKB99, exerts a range of anti-tumor activities in lung cancer. Here, we found that upregulation of
Potential application of natural compounds in ischaemic stroke: Focusing on the mechanisms underlying “lysosomocentric” dysfunction of the autophagy-lysosomal pathway
Authors: Yueyang Liu, Qingbo Liu, Hanxiao Shang, Jichong Li, He Chai, Kaixuan Wang, Zhenkun Guo, Tianyu Luo, Shiqi Liu, Yan Liu, Xuemei Wang, Hangyi Zhang, Chunfu Wu, Shao-Jiang Song, Jingyu Yang
Journal: Pharmacology & Therapeutics (2024)
Strategies for Overcoming Obstacles to Hands-on Cosmetic and Laser Training in Dermatology Residency
Authors: Bianca Y Kang, Miguel Aristizabal, Erik J Stratman, Jenny C Hu, Vesna Petronic-Rosic, Kira Minkis, Rachel Elsanadi, Gabriella Alvarez, Umer Nadir, Kristen M Kelly, Sami K Saikaly, Diana Bolotin, Yakir S Levin, Jeffrey S Orringer, Murad Alam
Journal: Journal of the American Academy of Dermatology (2024)
Senoinflammation as the underlying mechanism of aging and its modulation by calorie restriction
Authors: Sang Gyun Noh, Hyun Woo Kim, Seungwoo Kim, Ki Wung Chung, Young-Suk Jung, Jeong-Hyun Yoon, Byung Pal Yu, Jaewon Lee, Hae Young Chung
Journal: Ageing Research Reviews (2024)
HDAC7 is a potential therapeutic target in acute erythroid leukemia
Authors: Wenyu Zhang, Keita Yamamoto, Yu-Hsuan Chang, Tomohiro Yabushita, Yangying Hao, Ruka Shimura, Jakushin Nakahara, Shiori Shikata, Kohei Iida, Qianyi Chen, Xichen Zhang, Toshio Kitamura, Susumu Goyama
Journal: Leukemia (2024)